Head-To-Head Survey: Champions Oncology (NASDAQ:CSBR) & Context Therapeutics (NASDAQ:CNTX)

Champions Oncology (NASDAQ:CSBR) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Earnings and Valuation

This table compares Champions Oncology and Context Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$56.94 million	1.42	$4.70 million	($0.16)	-36.50
Context Therapeutics	N/A	N/A	-$36.12 million	($0.42)	-1.46

Champions Oncology has higher revenue and earnings than Context Therapeutics. Champions Oncology is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 47.0% of Champions Oncology shares are owned by company insiders. Comparatively, 4.8% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Champions Oncology and Context Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-3.94%	-57.31%	-7.51%
Context Therapeutics	N/A	-59.95%	-54.78%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Champions Oncology and Context Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1	0	0	0	1.00
Context Therapeutics	1	0	7	1	2.89

Context Therapeutics has a consensus price target of $6.17, suggesting a potential upside of 903.36%. Given Context Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Context Therapeutics is more favorable than Champions Oncology.

Risk and Volatility

Champions Oncology has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500.

About Champions Oncology

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

About Context Therapeutics

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.